Jeff Evanson, Chief Commercial Officer at Outlook Therapeutics, Inc. (OTLK), bought 35,200 shares at $1.34 ($47K) on 2021-12-03, disclosed to the SEC on 2021-12-06.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| OTLK | SELL | 2023-01-19 | $330K | — | Filing → |
| OTLK | SELL | 2021-02-25 | $18K | — | Filing → |
| OTLK | SELL | 2021-02-17 | $291K | — | Filing → |